Table 1. Getting started. Selected list of companies that Emory University, Institut National de la Santé et de la Recherche Médicale (INSERM), Max Planck Innovation GmbH, Northwestern University, University of Oxford and The University of Chicago say they have spun out. Money raised from equity/debt unless otherwise noted and may exceed the amounts listed. In certain cases where date of financings were not available, current exchange rates were applied.

 

Company

 

Technology summary

 

Year founded

 

Location

 

$ raised

 

Emory University

 

altiris Therapeutics

 

Small molecules against CXC chemokine receptor 4 (CXCR4) to treat cancer and HIV

 

2005

 

Atlanta, Ga.

 

$38.6M

 

ALVitae Pharmaceuticals Inc.

 

Diagnostics and therapeutics for cancer

 

2005

 

San Ramon, Calif.

 

Not available

 

AxoGen Inc.

 

Therapeutic device for peripheral nerve repair and regeneration

 

2002

 

Alachua, Fla.

 

$19.6M

 

AxoTect Inc.

 

Calpain inhibitors for chemotherapy-induced pain

 

2005

 

Atlanta, Ga.

 

Not available

 

BioSequent LLC

 

Elastin-mimetic protein triblock copolymers for use in cardiovascular grafts

 

2007

 

Atlanta, Ga.

 

Not available

 

Cardiovascular Prevention Diagnostics LLC

 

Diagnostics based on oxidative stress biomarkers

 

2003

 

Atlanta, Ga.

 

Not available

 

Cougar Biotechnology Inc. (NASDAQ:CGRB) (being acquired by Johnson & Johnson (NYSE:JNJ))

 

Noscapine and noscapine derivatives for cancer

 

2003

 

Los Angeles, Calif.

 

$184.6M

 

Crystalplex Corp.

 

Quantum dots for optoelectronic, security and life-science applications

 

2003

 

Pittsburgh, Pa.

 

$100K

 

Curry Pharmaceuticals

 

Curcumin-based therapeutics for dermatology, cancer, inflammation and autoimmune diseases

 

2003

 

Research Triangle Park, N.C.

 

Not available

 

GeoVax Labs Inc.

 

HIV vaccines

 

2001

 

Atlanta, Ga.

 

$740K

 

GSH Biomedical Ltd.

 

Glutathione to prevent influenza infection

 

2001

 

Liverpool, U.K.

 

Not available

 

iThemba Pharmaceuticals Pty Ltd.

 

Antivirals and antibacterials

 

2001

 

Mpumalanga,
South Africa

 

$4M

 

NeurOp Inc.

 

pH sensitive NMDAR antagonists

 

2002

 

Atlanta, Ga.

 

$2.2M ($500K from angels via convertible debt; $1.7M in NIH grants)

 

RayBiotech Inc.

 

Protein array and antibody analysis systems

 

2002

 

Atlanta, Ga.

 

Not available

 

Revitus Inc. (merged with BioVascular Inc. in 2007)

 

Thrombopoietin antagonists to prevent heart attacks and stroke

 

2004

 

Portland, Ore.

 

Not available

 

RFS Pharma LLC

 

Antivirals for HIV and HCV

 

2004

 

Tucker, Ga.

 

$400K in grants

 

SiGen Pharmaceuticals

 

Compounds that improve the efficacy of small interfering RNAs

 

2006

 

San Ramon, Calif.

 

Undisclosed angels

 

Sla'inte Bioceuticals Inc.

 

Sphingolipids for cancer and inflammatory diseases

 

2002

 

Marietta, Ga.

 

Not available

 

Zetra Biologicals LLC

 

Vaccines for pandemic influenza and other infectious diseases

 

2007

 

Atlanta, Ga.

 

Undisclosed grants

 

INSERM

 

 

 

 

 

CellVir S.A.

 

Retrovirals for HIV

 

2006

 

Evry, France

 

$347K

 

DNA Therapeutics S.A.

 

Oligonucleotides to treat cancer

 

2006

 

Evry, France

 

$4.1M

 

Genoscreen

 

Functional genomics and proteomics services

 

2001

 

Lille, France

 

$920K

 

Metagenex

 

Diagnostics that detect rare cells in blood

 

2001

 

Paris, France

 

$3.7M

 

Neorphys

 

Therapeutics for postoperative pain and female sexual dysfunction

 

2005

 

Nimes, France

 

$2.9M

 

Neurokin S.A.

 

Cyclin-dependent kinase inhibitors for stroke and epilepsy

 

2003

 

Marseille, France

 

$625K

 

Pharmaxon S.A.

 

Adhesion molecule modulators for spinal cord injury, neurodegenerative disease and glioma

 

2004

 

Marseille, France

 

$611K

 

TcL Pharma S.A.

 

Antibodies to prevent organ transplant rejection

 

2007

 

Nantes, France

 

$833K

 

TcLand Expression S.A.

 

Tests to predict organ transplant rejection

 

2002

 

Nantes, France

 

$12M

 

TxCell S.A.

 

Cell therapies for inflammatory diseases

 

2001

 

Sophia Antipolis, France

 

$29M

 

Vaxon-Biotech

 

Cancer vaccines based on cryptic peptides

 

2004

 

Evry Genopole, France

 

$2.5M

 

Max Planck Innovation

 

 

 

 

 

Affectis Pharmaceuticals AG

 

Therapeutics for psychiatric and inflammatory disorders

 

2002

 

Martinsried Germany

 

$24.9M

 

Alnylam Pharmaceuticals Inc. (NASAQ:ALNY)

 

RNAi for infectious diseases and neurology

 

2002

 

Cambridge, Mass.

 

$246M

 

AmVac AG

 

Immune therapies and vaccines for gynecology, urology and respiratory diseases

 

2005

 

Zug, Switzerland

 

Not available

 

amYmed GmbH

 

Immunoreagents for diagnosing amyloid diseases

 

2006

 

Martinsried, Germany

 

Not available

 

Autodisplay Biotech GmbH

 

Production of biocatalysts and bioanalytical tools

 

2008

 

Dusseldorf, Germany

 

Not available

 

Capsulution NanoScience AG (merged with Nanodel Technologies GmbH in 2008)

 

Nanotechnology for drug delivery and diagnostics

 

2000

 

Berlin, Germany

 

$2.8M

 

Direvo Biotech AG

 

Bioengineered enzymes for biorefineries and food and feed markets (sold biopharmaceuticals business to
Bayer AG (Xetra:BAY) in 2008)

 

2000

 

Cologne, Germany

 

$35.4M

 

IonGate Biosciences GmbH

 

Membrane measurement tools

 

2000

 

Frankfurt, Germany

 

$8.2M

 

Jado Technologies GmbH

 

Small molecules for allergies and infectious diseases

 

2001

 

Dresden, Germany

 

$10.9M

 

Kinaxo Biotechnologies GmbH

 

Cellular target profiling services

 

2005

 

Martinsried, Germany

 

$764K

 

RNAx GmbH

 

RNA screens

 

2002

 

Berlin, Germany

 

Not available

 

Scienion AG

 

Microarrays for low-volume liquid handling

 

2001

 

Dortmund, Germany

 

$10.9M

 

SuppreMol GmbH

 

Methods to block autoimmune diseases by inhibiting the activation of B cells by immune complexes

 

2002

 

Martinsried, Germany

 

$24.9M

 

U3 Pharma AG (acquired by
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) in 2008)

 

Antibodies for cancer

 

2001

 

Martinsried, Germany

 

$53.7M

 

Northwestern University

 

 

 

 

 

 

 

 

 

American BioOptics LLC

 

Diagnostics for colorectal cancer

 

2006

 

Evanston, Ill.

 

>$16M in grants

 

NanoInk Inc.

 

Nanotechnology for life science and semiconductor industries

 

2001

 

Skokie, Ill.

 

>$9M

 

Nanosphere Inc. (NASDAQ:NSPH)

 

Nanotechnology-based diagnostics

 

2000

 

Northbrook, Ill.

 

$194.7M

 

Viamet Pharmaceuticals Inc.

 

Metalloenzyme inhibitors for infectious diseases and cancer

 

2005

 

Research Triangle Park, N.C.

 

$6.25M

 

University of Oxford

 

 

 

 

 

Celleron Therapeutics Ltd.

 

CancerNav technology that identifies biomarkers of a tumor's sensitivity to a specific cancer drug

 

2005

 

Oxford, U.K.

 

Not available

 

Crysalin Ltd.

 

Crysalin lattice nanotechnology for tailored crystal formation

 

2007

 

Oxford, U.K.

 

Not available

 

Cytox Ltd.

 

Genetic tests for Alzheimer's disease

 

2006

 

Birmingham, U.K.

 

Not available

 

Eykona Technologies Ltd.

 

Imaging technology for advanced wounds

 

2007

 

Oxford, U.K.

 

Undisclosed

 

Glycoform Ltd.

 

Sugar chemistry and protein glycosylation technology to produce biosimilars

 

2002

 

Abingdon, U.K.

 

$2.8M

 

g-Nostics

 

Pharmacogenetic test for smoking cessation products

 

2004

 

Oxford, U.K.

 

$4M

 

InhibOx Ltd.

 

Computational drug discovery

 

2001

 

Oxford, U.K.

 

Not available

 

Oxford BioDynamics Ltd.

 

Chromosomal Confirmation Fingerprinting technology for detecting aberrant gene expression

 

2007

 

Oxford, U.K.

 

$10M

 

Oxford Biosensors Ltd.

 

Multisensor, dry enzyme system for analyte measurement

 

2000

 

Yarnton, U.K.

 

Not available

 

Oxford Immunotec Ltd.

 

Infectious disease diagnostics

 

2002

 

Oxford, U.K.

 

$57.2M

 

Oxford Nanopore Technologies Ltd.

 

Nanopore sequencing technology for label-free, single-molecule DNA sequencing and molecular sensing

 

2005

 

Kidlington, U.K.

 

$19.8M

 

Oxford-Emergent Tuberculosis Consortium Ltd.

 

Joint venture between University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) to develop MVA85A tuberculosis vaccine

 

2008

 

Oxford, U.K.

 

Not available

 

Particle Therapeutics Ltd.

 

Drug delivery and reformulation

 

2006

 

Oxford, U.K.

 

Not available

 

Pharminox Ltd.

 

Small molecules for cancer

 

2002

 

Oxford, U.K.

 

$7M

 

ReOx Ltd.

 

Therapeutics that modulate hypoxia-inducible factor-related enzymes for cardiovascular diseases

 

2003

 

Oxford, U.K.

 

Not available

 

RioTech Pharmaceuticals Ltd.

 

HCV therapeutics

 

2003

 

London, U.K.

 

$1.4M

 

Summit Corp. plc (LSE:SUMM)

 

Drug discovery and toxicology services

 

2003

 

Abingdon, U.K.

 

$45.1M

 

Surface Therapeutics Ltd.
(acquired by Serentis Inc. in 2007)

 

Therapeutics for inflammatory epithelial diseases

 

2004

 

Oxford, U.K.

 

Not available

 

Zyentia Ltd.

 

Modified human calcitonin for osteoporosis

 

2002

 

Cambridge, U.K.

 

$2.8M

 

University of Chicago

 

 

 

 

 

Anagen Therapeutics Inc.

 

Therapies for androgen and nuclear receptor-related diseases

 

2002

 

Chicago, Ill.

 

Not available

 

Maroon Biotech Corp.

 

Surfactant chaperones for trauma, spinal cord compression and malignant hypothermia

 

2002

 

Chicago, Ill.

 

Not available

 

Midway Pharmaceuticals Inc.

 

Therapeutics for GI tract diseases

 

2005

 

Spring House, Pa.

 

$500K

 

NephRx Corp.

 

Therapeutics for kidney failure and GI tract diseases

 

2001

 

Kalamazoo, Mich.

 

>$2.2M